AA
AAVXF.US ABIVAX Société Anonyme
- Market cap
- USD 7.42B
- P/E
- -
- P/B
- 29.43x
- ROE
- -90.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AAVXF.US undervalued?
Graham numberThe Graham number of ABIVAX Société Anonyme cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABIVAX Société Anonyme fundamental analysis
No fundamental analysis for ABIVAX Société Anonyme yet.
ABIVAX Société Anonyme stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in…
Full company profileABIVAX Société Anonyme financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ABIVAX Société Anonyme annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 151K | 356K | 815K | -7.00K | 14.0K | 37.0K | 4.58M | 4.62M | 10.8M | 0.00 | 0.00 |
| Gross Profit | -14.5M | -10.1M | -14.6M | -87.0K | -52.0K | -119K | 4.51M | 4.49M | 10.8M | -1.07M | - |
| Operating Income | -18.2M | -14.2M | -19.1M | -33.3M | -39.6M | -52.2M | -56.6M | -127M | -173M | -251M | -281M |
| EBITDA | -17.9M | -14.1M | -19.3M | -33.2M | -37.7M | -38.7M | -53.3M | -133M | -172M | -249M | -335M |
| Net Income | -14.3M | -11.2M | -15.8M | -30.6M | -37.6M | -41.4M | -69.8M | -148M | -176M | -336M | -332M |
| EPS | -1.47 | -1.13 | -1.55 | -2.51 | -2.62 | -2.47 | -3.13 | -3.43 | -2.80 | -4.83 | -4.17 |
| Balance Sheet | |||||||||||
| Total Assets | 60.6M | 53.8M | 54.0M | 51.7M | 71.3M | 110M | 73.4M | 327M | 205M | 584M | 462M |
| Total Liabilities | 3.88M | 5.64M | 19.4M | 39.9M | 66.6M | 81.6M | 71.5M | 131M | 165M | 129M | 95.9M |
| Shareholders' Equity | 56.7M | 48.2M | 34.7M | 11.8M | 4.67M | 28.8M | 1.88M | 196M | 40.6M | 455M | 366M |
| Cash & Short-term Investments | 23.0M | 17.0M | 13.0M | 9.77M | 29.3M | 60.7M | 27.0M | 261M | 144M | 530M | 411M |
| Total Debt | 2.52M | 262K | 10.9M | 20.7M | 34.0M | 53.4M | 46.7M | 59.0M | 97.4M | 32.1M | 1.21M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.6M | -8.45M | -14.6M | -27.5M | -29.8M | -45.7M | -65.6M | -97.1M | -154M | -162M | -205M |
| Capital Expenditure | 721K | 979K | 763K | 941K | 898K | 1.64M | 3.97M | 265K | 643K | 142K | 332K |
| Free Cash Flow | -16.3M | -9.43M | -15.4M | -28.4M | -30.7M | -47.3M | -69.5M | -97.4M | -155M | -162M | -205M |
| Ratios | |||||||||||
| ROE | -25.2% | -23.3% | -45.7% | -260.0% | -803.6% | -143.7% | -3,711.3% | -75.4% | -434.3% | -73.8% | -90.6% |
| ROA | -23.6% | -20.9% | -29.3% | -59.2% | -52.7% | -37.5% | -95.2% | -45.2% | -85.9% | -57.5% | -71.8% |
| Net Profit Margin | -9,475.5% | -3,152.2% | -1,941.5% | - | -268,221.4% | -111,775.7% | -1,524.0% | -3,197.1% | -1,633.1% | - | - |
| Debt to Equity | 0.04x | 0.01x | 0.31x | 1.76x | 7.27x | 1.86x | 24.83x | 0.30x | 2.40x | 0.07x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ABIVAX Société Anonyme dividends
ABIVAX Société Anonyme has not paid dividends in the last 9 fiscal years.
Who owns ABIVAX Société Anonyme
- Insiders 3.96%
- Institutions 52.64%
- Public & others 43.39%
- Shares outstanding 87.5M
- Free float 65.0M
ABIVAX Société Anonyme company profile
- Company name
- ABIVAX Société Anonyme
- Ticker
- AAVXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 98
- Fiscal year end
- December
- Address
- 7-11 Boulevard Haussmann, Paris, France, 75009
- Phone
- 33 1 53 83 09 63
- Website
- abivax.com
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme management
10- Mr. Marc M. P. de Garidel M.B.A.CEO & Director · born 1958
- Mr. Didier BlondelEVP, CFO & Board Secretary · born 1964
- Mr. Timothy P. Kelly M.B.A.Chief Technical Officer · born 1969
- Mr. Patrick MalloySenior VP & Head of Investor Relations
- Ms. Ida HatoumChief People & Compliance Officer · born 1975
- Mr. James BergerGlobal Head of Marketing
- Mr. Pierre Courteille M.B.A.Chief Business Officer · born 1969
- Hema KeshavaSenior Vice President of Finance
- Mr. Chris Rabbat Ph.D.Chief Medical Officer
- Kevin Shan Ph.D.VP & Global Head of Biometrics